Michael Sofia
2020
In 2020, Michael Sofia earned a total compensation of $1.2M as Chief Scientific Officer at Arbutus Biopharma Corp, a 18% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $188,770 |
|---|---|
| Option Awards | $605,458 |
| Salary | $439,000 |
| Other | $9,975 |
| Total | $1,243,203 |
Sofia received $605.5K in option awards, accounting for 49% of the total pay in 2020.
Sofia also received $188.8K in non-equity incentive plan, $439K in salary and $10K in other compensation.
Rankings
In 2020, Michael Sofia's compensation ranked 7,679th out of 13,090 executives tracked by ExecPay. In other words, Sofia earned more than 41.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 7,679 out of 13,090 | 41st |
Division Manufacturing | 3,241 out of 5,621 | 42nd |
Major group Chemicals And Allied Products | 1,310 out of 2,254 | 42nd |
Industry group Drugs | 1,134 out of 1,954 | 42nd |
Industry Pharmaceutical Preparations | 847 out of 1,459 | 42nd |
Source: SEC filing on April 8, 2021.
Sofia's colleagues
We found two more compensation records of executives who worked with Michael Sofia at Arbutus Biopharma Corp in 2020.
News
Arbutus Biopharma Corp CEO William Collier's 2023 pay jumps 28% to $3.4M
April 10, 2024
Arbutus Biopharma Corp CEO William Collier's 2022 pay slips 18% to $2.6M
April 12, 2023
Arbutus Biopharma Corp CEO William Collier's 2021 pay rises 18% to $3.2M
April 11, 2022
Arbutus Biopharma Corp CEO William Collier's 2020 pay rises 17% to $2.7M
April 8, 2021
Arbutus Biopharma Corp CEO Mark Murray's 2019 pay jumps 50% to $3.8M
April 24, 2020